A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

第2相完了 NCT05258071

対象疾患	Parkinson Disease
相	第2相
スポンサー	Integrative Research Laboratories AB
ステータス	完了
参加者数	104 名
介入（薬剤）	Pirepemat
開始日	2022年6月15日
完了日	2024年12月4日
結果公開日	2026年7月9日

概要

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.

Baseline to end of full dose treatment (up to Day 84). · % of baseline fall rate

Pirepemat 300 mg	76.9 ± 72.05 % of baseline fall rate
Pirepemat 600 mg	64.5 ± 49.18 % of baseline fall rate
Placebo	68.9 ± 90.22 % of baseline fall rate

p-value	0.5753
Median ratio	0.973 (95% CI 0.706–1.274)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers — Rutgers, The State University of New Jersey
Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский